Omeprazole Almus

Omeprazole, the active ingredient in Omeprazole Almus, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Omeprazole Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Almus is a proton pump inhibitor that acts on the gastric acid secretion pathway.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - NSAID‑induced ulcer prophylaxis: reduces the risk of ulcer formation in patients requiring long‑term non‑steroidal anti‑inflammatory drug therapy.

Adverse reactions to omeprazole are generally mild to moderate and vary with duration of therapy.

Common Side Effects: - Headache: mild, transient headache reported in clinical studies. - Diarrhoea: loose stools occurring in a minority of patients. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements in some users.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Hypomagnesemia: low serum magnesium with prolonged use. - Vitamin B12 deficiency: reduced absorption with long‑term therapy. - Stevens‑Johnson syndrome: rare severe skin reaction. - Acute interstitial nephritis: inflammation of kidney interstitium. - Hepatic injury: rare cases of liver enzyme elevation.

When prescribing omeprazole, clinicians should consider several safety aspects.

- Assess renal and hepatic function: adjust use if significant impairment exists. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: watch for nutrient deficiencies such as magnesium and vitamin B12. - Evaluate infection risk: prolonged acid suppression may increase susceptibility to gastrointestinal infections. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect may increase cardiovascular risk. - Atazanavir: decreased absorption leading to loss of antiviral efficacy. - Warfarin: potential increase in INR, requiring closer monitoring.

Moderate Interactions (Monitor Closely): - Phenytoin: may lower serum levels, reducing seizure control. - Digoxin: increased serum concentration, risk of toxicity. - Methotrexate: elevated levels, especially with high‑dose regimens. - Iron supplements: reduced absorption; separate dosing by at least 2 hours.